MAD1L1 as a Radioligand Therapy Target
MAD1L1, mitotic arrest deficient 1 like 1, is a cell-surface protein. In Human Protein Atlas immunohistochemistry, MAD1L1 staining is highest in pancreatic cancer (100% of samples positive), lymphoma (100% of samples positive) and bladder cancer (100% of samples positive). Clinical status: Discovery-stage (no clinical drug program).
Is MAD1L1 a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in pancreatic cancer, 100% of samples positive.
- ❔ Internalization: Not yet assessed.
- ⚠️ Clinical precedent: Discovery-stage (no clinical drug program)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
MAD1L1 expression in cancer
Protein expression of MAD1L1 across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Pancreatic Cancer | 0.89 | High | 100% |
| Lymphoma | 0.81 | High | 100% |
| Bladder Cancer | 0.81 | High | 100% |
| Melanoma | 0.79 | High | 100% |
| Glioma | 0.78 | High | 100% |
| Head and Neck Cancer | 0.75 | High | 100% |
| Thyroid Cancer | 0.75 | High | 100% |
| Gastric Cancer | 0.75 | High | 100% |
| Colorectal Cancer | 0.73 | High | 100% |
| Prostate Cancer | 0.70 | High | 100% |
| Cervical Cancer | 0.69 | High | 100% |
| Lung Cancer | 0.69 | High | 100% |
| Testicular Cancer | 0.69 | High | 100% |
| Ovarian Cancer | 0.69 | High | 92% |
| Endometrial Cancer | 0.67 | High | 100% |
| Breast Cancer | 0.64 | High | 100% |
| Skin Cancer | 0.61 | High | 100% |
| Neuroendocrine Tumors | 0.58 | High | 75% |
| Liver Cancer | 0.56 | High | 83% |
| Kidney Cancer | 0.52 | High | 73% |
Is MAD1L1 internalized?
Nuclens has not yet extracted internalization evidence for MAD1L1. Internalization matters for radioligands because an internalizing receptor traps the radionuclide inside the tumor cell. Run a full analysis to pull the latest literature.
MAD1L1 clinical trials
Discovery-stage (no clinical drug program). Nuclens hasn't indexed trials for MAD1L1 yet. Search ClinicalTrials.gov for MAD1L1 trials.
MAD1L1 normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See MAD1L1 in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
MAD1L1 gene essentiality (DepMap)
CRISPR knockout effect across 1258 cancer cell lines: -0.09 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related pancreatic cancer radioligand targets
EGFR · HER3 (ERBB3) · c-MET (MET) · Mesothelin (MSLN) · FAP · CEA (CEACAM5) · STEAP2 · SSTR2
See all radioligand therapy targets in pancreatic cancer.
See how MAD1L1 ranks against 15,000 targets for your indication.
Run a free analysisData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.